Recombinant Human CDCP1 protein (rFc Tag) (HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human CDCP1 protein (rFc Tag) (HPLC verified) (Eg2574)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg2574

---

Validation Data Gallery

• 

  Purity of Recombinant Human CDCP1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human CDCP1 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CDCP1 protein Phe30-Thr667 (Accession# Q9H5V8) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 64866
• Accession: Q9H5V8
• PredictedSize: 98.1 kDa
• SDS-PAGE: 105-120 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CDCP1, also called CD318, TRASK, and SIMA 135, is a transmembrane protein containing three CUB domains within the extracellular region and a hexalysine stretch within the cytoplasmic region. CDCP1 is a novel marker for hematopoietic stem cells. CDCP1 is overexpressed in a variety of malignant tumors including respiratory tumors, digestive system cancers, hematological malignancies and urogenital cancers. It has been recognized as a promising diagnostic biomarker and a potential target for disrupting cancer progression.

References:

1.Conze T, et al. (2003)  Ann N Y Acad Sci. 996:222-6. 
2.Wortmann A, et al. (2009) IUBMB Life. 61(7):723-30. 
3.Khan T, et al. (2021) Cancer Res. 1;81(9):2259-2269.
4.Qi X, et al. (2022) Life Sci. 15;301:120600.